Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-up.

Iddo Z Ben-DovYonatan OsterKeren TzukertTalia AlsterRaneem BaderRuth IsraeliHaya AsayagMichal AharonIdo BursteinHadas Pri-ChenAshraf ImamRoy AbelIrit Mor-Yosef LeviAbed KhalailehEsther Oiknine-DjianAharon BlochDana G WolfMichal Dranitzki Elhalel

Published in: Journal of nephrology (2022)

Dialysis patients, and more strikingly kidney transplant recipients, mounted reduced antibody response to COVID-19 mRNA vaccination. Lesser humoral response was associated with more infections. Measures to identify and protect non-responsive patients are required.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
ejection fraction
newly diagnosed
prognostic factors
coronavirus disease
sars cov
binding protein